Skip to content
ContentLora

    Tip: press / anywhere to search.

    Analysis

    From optogenetics to psychiatry: how close are new treatments?

    Optogenetics has mapped circuits behind depression-like, anxiety-like and dissociative states in animals, and the 2026 Nobel committee credits it with improving understanding of psychiatric disorders.[1][2][3] As of October 2026, though, its only clinical trials described by the committee aim to restore vision. Whether its main psychiatric payoff comes from light-based therapy or from better targeting of existing tools is an open question.[4][5]

    Editor reviewedStrict sourcingUpdated AnalysisNeuroscience and brain-computer interfaces, Health and medicine, Life sciences
    Show:

    The question

    Optogenetics switches chosen nerve cells on or off with light.[6] Karl Deisseroth, who trained in psychiatry, developed it partly because the treatments he could offer patients were rarely effective.[7] With the method now honoured by the 2026 Nobel Prize, the question here is how close it is to helping people with depression, anxiety, addiction or psychosis.[8] This page is analysis, not medical advice. Anyone with mental-health symptoms should talk to a clinician.

    What we know

    Animal findings. In rodents, inhibiting or exciting specific midbrain dopamine neurons immediately induced or relieved several depression-like symptoms caused by chronic stress.[1] In mice, ketamine set off a 1-3 Hz rhythm in the retrosplenial cortex, and driving that rhythm with light reproduced dissociation-like behaviour.[2] Optogenetic work has also linked heart rhythm to anxiety, and has reversed Parkinson’s symptoms in mice.[9][10] The Nobel committee says the method has improved understanding of depression, anxiety, schizophrenia, Alzheimer’s and Parkinson’s.[3]

    Human evidence. The clinical trials the committee describes aim to restore vision in retinitis pigmentosa.[4] The first reported functional recovery came in a single blind patient, who was treated with a viral vector and light-projecting goggles.[11] In the 2020 dissociation study, one epilepsy patient showed a similar brain rhythm that tracked self-reported dissociation.[2] Since November 2023, Stanford’s Human Neural Circuitry program has studied real-time brain activity in patients with clinically placed electrodes.[12]

    Indirect routes. A 2015 mouse study designed low-frequency deep brain stimulation, combined with dopamine D1 receptor blockade, to mimic an optogenetic protocol. It produced a long-lasting loss of cocaine-adaptive behaviour.[5] The same paper notes that deep brain stimulation already treats some neurological and psychiatric conditions, but its effects are transient and its mechanisms largely unknown.[13]

    Pace. Deisseroth has written that optogenetics produced few findings in 2005-2009 before thousands of discoveries followed.[14]

    How to read the evidence

    The psychiatric case for optogenetics is strong as a research tool and still unproven as a therapy. The rodent studies show that specific cells can cause specific symptom-like behaviours, which is what the Nobel committee rewarded.[1][3] But an animal “depression-like” state is a model, not the human illness, so these results do not show that the same circuits drive depression in patients.

    The eye is a special case. Light reaches the retina naturally, and the vision result came from one patient.[11] Deep brain targets would need gene delivery plus implanted light sources, which adds risks beyond the eye case. That is our inference; no psychiatric optogenetic trial was described in the sources we reviewed.

    The indirect route looks nearer. The 2015 addiction study shows how a circuit found with optogenetics can point to a stimulation pattern for a device already used in people.[5][13] Human recording programs such as Stanford’s can then check whether animal circuits have human counterparts, as the single-patient dissociation finding hinted.[12][2] This overlaps with brain-computer interface work, whose readiness we assess in Are brain implants ready?.

    What could happen next

    Our estimate, with low confidence: over the next few years, optogenetics’ clinical influence on psychiatry is more likely to come through refined stimulation or drug targets than through light-based gene therapy in the brain. The reasons are the mouse-only evidence for refined DBS and the absence of described psychiatric trials as of October 2026.[5][4]

    Stanford describes using optogenetics in people with gene therapy, for example in paraplegia, as an eventual possibility. We would treat any date for that as speculative.[15] Controlled results from the vision trials will be the first real test of whether optogenetic therapy works beyond single cases.[4][11]

    Competing views

    Insights will improve existing treatments first

    Optogenetic findings in animals can be copied with tools already used in people, such as refined deep brain stimulation or drugs, and human recording programs can check whether the same circuits matter in patients.[5][2][12]

    Direct light-based therapy will follow

    Optogenetic gene therapy already restored partial vision in one blind patient, and researchers expect to extend it to hearing and, eventually, to other gene-therapy uses.[11][16][15]

    Psychiatric treatment is still far off

    The psychiatric evidence comes mostly from rodents, the only human functional result is a single eye case, and deep brain stimulation, the closest existing tool, has transient effects with unclear mechanisms.[1][11][13]

    Next in the crash course

    Neuroscience & BCI

    How brain mapping and connectomics work

    How scientists map every neuron and synapse with electron microscopy and AI, from the whole fly brain to a cubic millimetre of mouse and human cortex.

    More in Neuroscience & BCI

    Developing in Health

    Questions readers ask

    Can optogenetics treat depression?

    Not in people as of October 2026. In rodents, switching specific dopamine neurons on or off induced or relieved depression-like symptoms caused by chronic stress, but the clinical trials described by the Nobel committee aim to restore vision.[1][4]

    Why is optogenetics hard to use in human brains?

    It needs a light-sensitive protein delivered into chosen cells by gene transfer, plus a way to bring light to them. The one published human success did this in the eye, using a viral vector and light-projecting goggles.[6][11]

    Has optogenetics changed any existing treatment?

    In mice, researchers designed a refined form of deep brain stimulation that mimicked an optogenetic protocol and gave a long-lasting reversal of cocaine-adaptive behaviour. It has not been shown in people.[5]

    What did optogenetics reveal about ketamine?

    A 2020 study found ketamine triggered a slow rhythm in a part of the mouse cortex, and driving that rhythm with light reproduced dissociation-like behaviour; a similar rhythm in one epilepsy patient tracked self-reported dissociation.[2]

    Sources

    · 16 claims from 8 publishers

    Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.

    1. [1]

      A 2013 Nature study from Deisseroth's lab found that inhibiting or exciting specific midbrain dopamine neurons in rodents immediately induced or relieved multiple depression-like symptoms caused by chronic stress. confirmedas of 2012-12-12

    2. [2]

      A 2020 Nature study led by Deisseroth's lab found that ketamine induced a 1-3 Hz rhythm in retrosplenial cortex of mice, that driving this rhythm optogenetically recreated dissociation-like behaviour, and that a similar rhythm in one epilepsy patient correlated with self-reported dissociation. confirmedas of 2020-09-16

    3. [3]

      The Nobel committee says optogenetics has improved understanding of the distinguishing features of depression, anxiety, schizophrenia, Alzheimer's disease and Parkinson's disease. confirmedas of 2026-10-05

    4. [4]

      As of October 2026 the main clinical use of optogenetics is in trials to restore vision in people blinded by retinitis pigmentosa; in one person, a channelrhodopsin-like protein plus light-emitting glasses restored enough vision to locate and grasp objects. confirmedas of 2026-10-05

    5. [5]

      A 2015 Science study in mice found that low-frequency deep brain stimulation combined with dopamine D1 receptor blockade mimicked an optogenetic protocol that reversed cocaine-induced synaptic changes, giving a long-lasting loss of drug-adaptive behaviour. confirmedas of 2015-02-06

    6. [6]

      Optogenetics uses light-sensitive proteins called opsins, originally found in microbes, inserted into chosen nerve cells so that light can switch those cells on or off in a living brain. confirmedas of 2026-10-05

    7. [7]

      According to the Nobel committee, Deisseroth considered neurosurgery but was struck by patients' suffering during psychiatric training, and pursued new tools because the treatments he could offer were rarely effective and often had debilitating side effects. confirmedas of 2026-10-05

    8. [8]

      On 5 October 2026 the Nobel Assembly at Karolinska Institutet awarded the 2026 Nobel Prize in Physiology or Medicine jointly to Karl Deisseroth, Peter Hegemann and Georg Nagel "for their discoveries concerning light-gated ion channels and optogenetics". confirmedas of 2026-10-05

    9. [9]

      Deisseroth has used optogenetics to show that heart rhythm can affect emotion; forcing the heart to work harder can reinforce anxiety-like states. confirmedas of 2026-10-05

    10. [10]

      Stanford says Deisseroth and UCSF researcher Anatol Kreitzer used optogenetics to reverse Parkinson's symptoms in mice, and that his team identified a circuit controlling the desire for social interaction in mice. confirmedas of 2026-10-05

    11. [11]

      A 2021 Nature Medicine case report described the first partial functional recovery after optogenetic therapy in a neurodegenerative disease, in one blind patient with retinitis pigmentosa who received a viral vector encoding ChrimsonR and used engineered goggles. confirmedas of 2021-05-24

    12. [12]

      In November 2023 Deisseroth and collaborators launched Stanford's Human Neural Circuitry program, which studies real-time brain activity from patients with clinically placed electrodes in a specialised space at Stanford Hospital. confirmedas of 2026-10-05

    13. [13]

      The same paper notes that deep brain stimulation is used for neurological and psychiatric conditions, but its effects are transient and its mechanisms largely unknown. confirmedas of 2015-02-06

    14. [14]

      In a 2015 review Deisseroth wrote that optogenetics had few publications and limited findings in 2005-2009, followed by thousands of discoveries in the following years. confirmedas of 2015-09-01

    15. [15]

      Stanford says optogenetics may eventually be used in humans together with gene therapy, for example to restore function to people with paraplegia. reportedas of 2026-10-05· forecast

    16. [16]

      Researchers hope optogenetics could make cochlear implants for hearing loss more precise by activating the auditory nerve with light instead of electricity. confirmedas of 2026-10-05

    Revision history (1)
    1. Page created.

    Created Oct 11, 2026. Last reviewed by an editor on Oct 11, 2026. Next scheduled review: Jan 11, 2027.

    Cite this page

    "From optogenetics to psychiatry: how close are new treatments?." ContentLora, updated Oct 11, 2026. https://contentlora.com/analysis/optogenetics-psychiatry-translation

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.

    ☰ Contents